YZYafeng Zhu

Yafeng Zhu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yafeng Zhu has a total of 63 co-authors. Here are the top co-authors by number of shared publications:

  • Janne Lehtiö

    Department of Oncology and Pathology, Karolinska Institutet, SciLifeLab, Solna, Sweden.

    3 shared publications
  • Mei Yang

    Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

    3 shared publications
  • Lingshuo Wang

    Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

    2 shared publications
  • Anna Andersson

    Department of Medicine Solna, Translational Immunology Unit, Karolinska Institutet and University Hospital, 17177 Stockholm, Sweden

    1 shared publication
  • Annika Scheynius

    Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden

    1 shared publication
  • Benjamin Sigurgeirsson

    Science for Life Laboratory, School of Biotechnology, Royal Institute of Technology, 17121 Solna, Sweden

    1 shared publication

Latest Publications

  • Open Access

    Proteomics-based approach reveals the involvement of spliceosomal components SF3B and SerpinB9 in dermatofibrosarcoma protuberans

    by Yang Xie, Haifeng Li, Tian Liu, Lingshuo Wang, Mei Yang, Miaojian Wan, Jingang Huang, Yafeng Zhu

    Background: Dermatofibrosarcoma protuberans (DFSP) is a rare cutaneous soft tissue sarcoma which is prone to high recurrence rate, and the fibrosarcomatous transformation of DFSP (FS-DFSP) is associated with a poorer prognosis and significant metastatic potential. Although the translocation of regions of chromosomes 17 and 22 that results in COL1A1-PDGFB fusion is generally acknowledged as a key genetic feature of DFSP, there is no established salvage treatment following resistance to imatinib, which targets the PDGFB pathway. In this study, we performed quantitative proteomics analyses of DFSP tumor tissues and paired adjacent normal skin, to uncover novel molecular mechanisms and potential therapeutic targets. Findings were validated using immunohistochemistry, Western Blot, Real-Time Quantitative PCR and cell viability assay. Results: Pathway enrichment analysis including KEGG and GSEA revealed that spliceosome pathways and ECM-receptor interaction were associated with DFSP pathogenesis. The spliceosomal components SF3B, and SerpinB9, which is the endogenous inhibitor of granzyme B, were validated to be upregulated in tumor tissues. SerpinB9 was significantly overexpressed in the FS-DFSP subtype compared with the classic-type DFSP. Treatment with the SF3B1 inhibitor, Pladienolide-B, significantly reduced tumor cell viability. siRNA-mediated knockdown of SF3B1 and SF3B2, as well as Pladienolide-B treatment, inhibited SERPINB9 expression without affecting pre- SERPINB9 mRNA levels, suggesting splicing-dependent regulation. Additionally, quantitation of the tumor microenvironment cells using the MCP-counter algorithm indicated NK cells activation. The CD56 (NK cell surface marker), biomarkers of tumor-associated macrophage (TAM) such as CD14 and CD163, and transforming growth factor-β induced (TGFBI) which is associated with TAM infiltration stained positive in DFSP tumors. SERPINB9 mRNA expression showed a positive correlation with both NK cell abundance and FCGR3A (NK cell marker) mRNA level. Conclusions: SerpinB9 overexpression is associated with fibrosarcomatous features in DFSP and may represent a candidate prognosis biomarker. The SF3B/SERPINB9 axis is a potential therapeutic vulnerability, particularly in FS-DFSP. NK cell- and macrophage-related signatures were evident in DFSP tumor microenvironment, warranting further functional studies.

  • Differential protein expression analysis of quantitative mass spectrometry data using DEqMS

    by Yafeng Zhu, Olena Berkovska, Lingshuo Wang, Mei Yang, Henrik J. Johansson, Georgios Mermelekas, Mahshid Zarrineh, Dong Yin, Lukas M. Orre, Janne Lehtiö

    DEqMS is an R package-based statistical tool for differential protein expression analysis in quantitative mass spectrometry-based proteomics. It implements a robust Bayesian method for accurate variance estimation that accounts for the number of mass spectrometry features used for protein quantification (number of peptide precursors or peptide spectrum matches). Originally validated for data-dependent acquisition proteomics, DEqMS now extends to data-independent acquisition workflows, as demonstrated using both spike-in and real-world datasets. Given a peptide- or protein-level quantification table with mass spectrometry feature count as inputs, DEqMS outputs a protein- or gene-level results table containing fold changes and multiple statistics (t-values, P value, among others) adjusted according to mass spectrometry feature count. Here we detail the use of the DEqMS R package. This updated workflow broadens DEqMS's applicability, enabling researchers with basic R programming knowledge to identify proteins with significantly altered abundance between sample groups across diverse quantitative proteomics datasets. DEqMS is available to install at https://bioconductor.org/packages/DEqMS/ .


  • Open Access

    Proteogenomics-enabled discovery of novel small open reading frame (sORF)-encoded polypeptides in human and mouse tissues

    by Mei Yang, Yuting Xie, Lingshuo Wang, Irwin Jungreis, Tong Ou, Manolis Kellis, Jia Wang, Yafeng Zhu

    Small open reading frames (sORFs) encode an emerging class of functional proteins less than 100 amino acids in length. However, sORFs are incompletely characterized in mice and humans. The development of proteomics and Ribo-seq techniques has enabled the discovery of a number of sORF-encoded peptides (SEPs), but previous proteogenomics studies have been limited to a few cell lines or tissues. Given these limitations, a potentially vast number of sORFs remains to be discovered. We collected community-scale previously published proteomics data including one billion experimental spectra derived from a wide range of mouse and human tissues in order to identify novel sORFs and reveal the tissue expression status of novel and recently annotated sORF-encoded proteins. We have detected several novel sORFs in specific tissues, including a conserved protein-coding upstream overlapping ORF in HNRNPUL2 expressed in human lymphocytes, which may hold important biological functions. This work introduces a simple and efficient filtration strategy to detect novel sORFs. Our workflow will likely prove useful for future studies on sORFs in humans and other animals.


  • Open Access

    Generation of ENSEMBL-based proteogenomics databases boosts the identification of non-canonical peptides

    by Husen M. Umer, Yafeng Zhu, Julianus Pfeuffer, Timo Sachsenberg, Janne Lehtiö, Rui Branca, Yasset Perez-Riverol

    Summary: We have implemented the pypgatk package and the pgdb workflow to create proteogenomics databases based on ENSEMBL resources. The tools allow the generation of protein sequences from novel protein-coding transcripts by performing a three-frame translation of pseudogenes, lncRNAs, and other non-canonical transcripts, such as those produced by alternative splicing events. It also includes exonic out-of-frame translation from otherwise canonical protein-coding mRNAs. Moreover, the tool enables the generation of variant protein sequences from multiple sources of genomic variants including COSMIC, cBioportal, gnomAD, and mutations detected from sequencing of patient samples. pypgatk and pgdb provide multiple functionalities for database handling, notably optimized target/decoy generation by the algorithm DecoyPyrat . Finally, we perform a reanalysis of four public datasets in PRIDE by generating cell-type specific databases for 65 cell lines using the pypgatk and pgdb workflow, revealing a wealth of non-canonical or cryptic peptides amounting to more than 10% of the total number of peptides identified (43,501 out of 402,512). Availability: The software is freely available. pypgatk : ( https://github.com/bigbio/py-pgatk/ ), and pgdb : ( https://github.com/nf-core/pgdb ) Contact: Yasset Perez-Riverol ( yperez@ebi.ac.uk ), Rui Branca ( rui.mamede-branca@ki.se ) Supplementary information: Supplementary data are available online.


  • Identification of a thermostable cellobiose 2‐epimerase from Caldicellulosiruptor sp. Rt8.B8 and production of epilactose using Bacillus subtilis

    by Li Liangfei, Zhu Yafeng, Xu Kai, Xu Zheng

    BACKGROUND: Epilactose, a potential prebiotics, was derived from lactose through enzymatic catalysis. However, production and purification of epilactose are currently difficult due to powerless enzymes and inefficient downstream processing steps.RESULTS: The encoding gene of cellobiose 2‐epimerase (CE) from Caldicellulosiruptor sp. Rt8.B8 was cloned and expressed in Escherichia coli BL21(DE3). The enzyme was purified and it was suitable for industrial production of epilactose from lactose without by‐products, because of high kcat (197.6 s−1) and preferable thermostability. The Rt8‐CE gene was further expressed in the Bacillus subtilis strain. We successfully produced epilactose from 700 g L−1 lactose in 30.4% yield by using the recombinant Bacillus subtilis whole cells. By screening of a β‐galactosidase from Bacillus stearothermophilus (BsGal), a process for separating epilactose and lactose was established, which showed a purity of over 95% in a total yield of 69.2%. In addition, a mixed rare sugar syrup composed of epilactose and d‐tagatose was successfully produced from lactose through the co‐expression of l‐arabinose isomerase and β‐galactosidase.CONCLUSION: Our study shed light on the efficient production of epilactose using a food‐grade host expressing a novel CE enzyme. Moreover, an efficient and low‐cost process was attempted to obtain high purity epilactose. In order to improve the utilization of raw materials, the production process of mixed syrup containing epilactose and d‐tagatose with prebiotic properties produced from lactose was also established for the first time. © 2021 Society of Chemical Industry.


  • Open Access

    Increased expression of peptides from non-coding genes in cancer proteomics datasets suggests potential tumor neoantigens

    by Rong Xiang, Leyao Ma, Mingyu Yang, Zetian Zheng, Xiaofang Chen, Fujian Jia, Fanfan Xie, Yiming Zhou, Fuqiang Li, Kui Wu, et al.

    Neoantigen-based immunotherapy has yielded promising results in clinical trials. However, it is limited to tumor-specific mutations, and is often tailored to individual patients. Identifying suitable tumor-specific antigens is still a major challenge. Previous proteogenomics studies have identified peptides encoded by predicted non-coding sequences in human genome. To investigate whether tumors express specific peptides encoded by non-coding genes, we analyzed published proteomics data from five cancer types including 933 tumor samples and 275 matched normal samples and compared these to data from 31 different healthy human tissues. Our results reveal that many predicted non-coding genes such as DGCR9 and RHOXF1P3 encode peptides that are overexpressed in tumors compared to normal controls. Furthermore, from the non-coding genes-encoded peptides specifically detected in cancers, we predict a large number of “dark antigens” (neoantigens from non-coding genomic regions), which may provide an alternative source of neoantigens beyond standard tumor specific mutations.


  • Open Access

    Proteogenomics produces comprehensive and highly accurate protein-coding gene annotation in a complete genome assembly ofMalassezia sympodialis

    by Yafeng Zhu, Pär G. Engström, Christian Tellgren-Roth, Charles D. Baudo, John C. Kennell, Sheng Sun, R. Blake Billmyre, Markus S. Schröder, Anna Andersson, Tina Holm, et al.

    Complete and accurate genome assembly and annotation is a crucial foundation for comparative and functional genomics. Despite this, few complete eukaryotic genomes are available, and genome annotation remains a major challenge. Here, we present a complete genome assembly of the skin commensal yeast Malassezia sympodialis and demonstrate how proteogenomics can substantially improve gene annotation. Through long-read DNA sequencing, we obtained a gap-free genome assembly for M. sympodialis (ATCC 42132), comprising eight nuclear and one mitochondrial chromosome. We also sequenced and assembled four M. sympodialis clinical isolates, and showed their value for understanding Malassezia reproduction by confirming four alternative allele combinations at the two mating-type loci. Importantly, we demonstrated how proteomics data could be readily integrated with transcriptomics data in standard annotation tools. This increased the number of annotated protein-coding genes by 14% (from 3612 to 4113), compared to using transcriptomics evidence alone. Manual curation further increased the number of protein-coding genes by 9% (to 4493). All of these genes have RNA-seq evidence and 87% were confirmed by proteomics. The M. sympodialis genome assembly and annotation presented here is at a quality yet achieved only for a few eukaryotic organisms, and constitutes an important reference for future host-microbe interaction studies.